As per the renegotiated terms, Ipsen returns its rights for territories outside of North America and Japan in exchange for milestone payments and royalties based on future partnering and commercial success of fipamezole.
Santhera regains the worldwide rights to the development and commercialization of fipamezole, its first-in-class selective adrenergic alpha-2 receptor antagonist for the management of levodopa-induced Dyskinesia in Parkinson’s Disease.
Ipsen retains a call option for worldwide license to the program under certain conditions.
Santhera CEO Thomas Meier said that in the short term, the focus of their investments remains on Catena and its multiple product opportunities in neuromuscular and mitochondrial orphan indications.